THOR MEDICAL Oslo, Norway ,16 November 2020 Nordic Nanovector ASA (OSE: NANO) announces that it will report its results for the third quarter 2020 on Thursday,19 November 2020 . A presentation byNordic Nanovector's senior management team will be webcast live the same day at8:30am CET . The webcast can be accessed from www.nordicnanovector.com in the section: Investors & Media and a recording will also be available on this page after the event. The results report and the presentation will be available at www.nordicnanovector.com in the section: Investors & Media/Reports and Presentation/Interim Reports/2020 from7:00am CET the same day. For further information, please contact: IR enquiries Malene Brondberg, CFO Cell: +44 7561 431 762 Email: ir@nordicnanovector.com Media EnquiriesMark Swallow /Frazer Hall /David Dible (Citigate Dewe Rogerson ) Tel: +44 203 926 8535 Email: nordicnanovector@citigatedewerogerson.com AboutNordic Nanovector :Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearlyUSD 29 billion by 2026.Nordic Nanovector retains global marketing rights to Betalutin® and intends to actively participate in the commercialisation of Betalutin® in the US and other major markets. Further information can be found at www.nordicnanovector.com. This information is subject to a duty of disclosure pursuant to Sections 4-2 and 5-12 of the Securities Trading Act.
Click here for more information
© Oslo Bors ASA, source
